Sanofi Ventures
VC Fund
Cambridge, United States
Sanofi Ventures is a VC fund in Cambridge focused on Biotechnology and Health Care. Sanofi Ventures is the corporate venture capital arm of Sanofi. We have the ability to seed and to lead financings in early-stage companies with innovative ideas and transformative new products and technologies that are of strategic interest to Sanofi. Among these areas are rare diseases, oncology, immunology and inflammation, vaccines, potential cures in other core areas of Sanofi’s business footprint, and digital health and data science solutions.
- Total investments:
- 131
- Last investment:
- Lead investor:
- 25%
- Fund size:
- $625M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Sanofi Ventures invests in
Stages Sanofi Ventures invests in
Countries Sanofi Ventures invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 9 contacts → | |||
Round size
- Series A
- $9M–$140M
- Series B
- $30M–$135M
- Series C
- $30M–$200M
Investment Focus
Industry
- Biotechnology 64 (49%)
- Health Care 50 (38%)
- Medical 35 (27%)
- Therapeutics 30 (23%)
- Pharmaceutical 24 (18%)
Stage
- Series B 45 (34%)
- Series A 32 (24%)
- Series C 17 (13%)
- Seed 8 (6%)
- Venture - Series Unknown 5 (4%)
Country
- United States 65 (50%)
- United Kingdom 5 (4%)
- France 3 (2%)
- Israel 3 (2%)
- Denmark 2 (2%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Christopher Gagliardi
Principal
|
Principal | Total investments: 10 | Find email | |
Alan Walts
Managing Director
|
Managing Director | Total investments: 2 | Find email | |
Alba Zurriaga Carda
Director of Investments
|
Director of Investments | Total investments: 0 | Find email | |
Charles Thyne
Industrial Operations
|
Industrial Operations | Total investments: 0 | Find email | |
Cris De Luca
Partner, Digital Investments, Sanofi Ventures
|
Partner, Digital Investments, Sanofi Ventures | Total investments: 7 | Find email | |
| See all 9 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| OMass Therapeutics is a drug discovery company exploiting novel mass spectrometry platforms to develop therapeutics against challenging disease targets. | $310M / Series C / Oct 15, 2026 | ||
| Matchpoint is a biotechnology company harnessing the power of covalency to discover precision covalent medicines to transform the treatment of immune diseases and other serious illnesses. The company's proprietary Advanced Covalent Exploration (ACE) platform integrates advanced chemoproteomics, machine learning, and covalent chemistry libraryevolution. Matchpoint has an emerging pipeline of novel covalent medicines, initially focused on immunology. | $150M / Series B / Oct 07, 2026 | ||
| Korsana Biosciences develops THETA-enabled antibody therapies for neurodegenerative diseases. The company focuses on shuttled monoclonal antibodies that cross the blood-brain barrier to reach central nervous system targets. Its lead program, KRSA-028, is an investigational anti-amyloid beta antibody for Alzheimer’s disease that uses a transferrinreceptor-based shuttle and Fc engineering to improve brain delivery and dosing. Korsana is also advancing additional THETA-based programs for undisclosed neurodegenerative indications. | $380M / Post-IPO Equity / Sep 08, 2026 | ||
| Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both autoimmunity and cancer. They leverage the systematic target validation and clinical insights gained by its founders to identify new targets. Their intensive use of bioinformatics to interrogate the transcriptome of human disease together with ex-vivovalidation in diseased tissue has uncovered new approaches to target key compartments of the immune system.The company was incorporated in 2015 and is based in Newton, Massachusetts. | $66M / Series D / Aug 18, 2026 | ||
| The Gene Expression Modulation System (GEMS) technology from Epic-Bio combines a DNA-binding protein, a tailored guide RNA, and any of a wide range of modulator proteins to generate a powerful new type of genetic medicine. GEMS medicines have the ability to precisely modify gene expression both in and out of the body. They are mutation-independent,which means that a single GEMS design can address the majority or all genetic subtypes of a disease. | $90M / Series C / Aug 11, 2026 | ||
| Expedition Therapeutics operates as an unincorporated association. | $115M / Series B / Aug 05, 2026 | ||
| Quant Health offers drug simulation, computational biology, clinical data science, respiratory, trial simulation, and oncology services. | $45M / Series B / Aug 04, 2026 | ||
| AdvanCell is an Australian radiopharmaceutical firm in the clinical stages that has developed the Targeted Alpha Therapy platform technology, a cutting-edge cancer treatment. | $315M / Series D / Jul 15, 2026 | ||
| Nura Bio revolutionizes the treatment of neurological diseases with novel, life-changing neuroprotective medicines. Nura Bio was conceived in 2018 by The Column Group and its scientific founders. | $73.8M / Series B / Jun 22, 2026 | ||
| Bionyra Pharma is a clinical-stage biopharmaceutical startup developing next-generation biologics for serious immune-mediated inflammatory diseases. | $165M / Series A / Jun 22, 2026 | ||
| See all 131 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Sanofi Ventures invest in?
Sanofi Ventures invests primarily in Biotechnology, Health Care and Medical startups, most often at Series B and Series A stage. Most of the 131 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does Sanofi Ventures invest in?
Sanofi Ventures typically joins rounds of $9M–$140M at Series A, $30M–$135M at Series B and $30M–$200M at Series C. These are whole funding-round sizes, not Sanofi Ventures's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds Sanofi Ventures took part in.
How do I contact Sanofi Ventures?
Public channels for Sanofi Ventures include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Sanofi Ventures?
The team at Sanofi Ventures includes Christopher Gagliardi (Principal), Alan Walts (Managing Director) and Alba Zurriaga Carda (Director of Investments), among 9 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
